Stay updated on Seagen Press Releases

Sign up to get notified when there's something new on the Seagen Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Seagen Press Releases page

  1. Check
    6 days ago
    Change Detected
    Summary
    The press-release listings, filters, navigation, and footer are absent, leaving the page blank.
    Difference
    21%
    Check dated 2026-11-09T13:43:55.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The press release list adds Pfizer’s October 27, 2026 announcement about ELREXFIO’s Phase 3 results in relapsed or refractory multiple myeloma, categorized under Prescription Medicines and Medicines. It no longer displays the August 27, 2026 COVID-19 vaccine approval announcement or its August 2026 archive heading.
    Difference
    2%
    Check dated 2026-11-02T13:54:47.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The press-release list adds Pfizer’s October 24, 2026 announcement of robust Phase 2 data for its 25-valent pediatric pneumococcal vaccine candidate and removes the August 4, 2026 second-quarter results and revenue-guidance announcement.
    Difference
    1%
    Check dated 2026-10-26T16:24:07.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The press-release listing adds Pfizer’s October 14, 2026 announcement about clinical advancements across infectious diseases at IDWeek 2026. It also removes the July 2026 LITFULO Phase 3 results release and its associated category labels.
    Difference
    2%
    Check dated 2026-10-19T20:39:16.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The press release list now features FDA approval of Pfizer’s TUKYSA regimen as front-line maintenance treatment for HER2-positive metastatic breast cancer, along with the company’s fourth-quarter 2026 dividend announcement. Earlier releases about TALZENNA’s priority review and EU authorization of an adapted COVID-19 vaccine are no longer listed.
    Difference
    4%
    Check dated 2026-10-13T03:50:17.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The listings now include October 2026 research updates on LITFULO and tilrekimig, with related Research and Pipeline categories. The Pfizer dividend announcement and a PADCEV/Keytruda FDA approval release are no longer listed.
    Difference
    4%
    Check dated 2026-10-05T19:55:20.000Z thumbnail image

Stay in the know with updates to Seagen Press Releases

Enter your email address, and we'll notify you when there's something new on the Seagen Press Releases page.